FCGRT

Fc fragment of IgG receptor and transporter

Score: 0.596 Price: $0.60 Medium Druggability Status: active Wiki: FCGRT

🧠 Neurodegeneration

HYPOTHESES

1

PAPERS

17

KG EDGES

41

DEBATES

1

3D Protein Structure

🧬 FCGRT — PDB 1I1A Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.51

Clinical Stage

Approved

Target Class

Transporter

Safety

0.70

Druggability Analysis

Drug Development0.75

Structural Tractability0.85

Target Class0.70

Safety Profile0.70

Key Metrics

PDB Structures:

24

Known Drugs:

1

Approved:

1

In Clinical Trials:

0

Drug Pipeline (1 compounds)

1 Approved

Druggability Rationale: FCGRT is highly druggable (score: 0.90) due to its well-characterized structure (24 PDB entries, 1.85 Å resolution), validated by the FDA-approved monoclonal antibody efgartigimod for myasthenia gravis. As a cell-surface transporter with extracellular epitopes, it is ideally suited for antibody-based therapeutics that can block FcRn-mediated IgG recycling without requiring intracellular penetration.

Mechanism: Monoclonal antibody blocking FcRn-mediated IgG recycling

Drug Pipeline (1 compounds)

1 Approved

Known Drugs:

efgartigimod (approved) — myasthenia gravis

Structural Data:

PDB (24) ✓AlphaFold ✓Cryo-EM ✓

3M17 3M1B 4K71 4N0U 5BJT+19 more

UniProt: A0AB39TYH5

🧬 3D Protein Structure

🧬 FCGRT — PDB 1I1A Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is less challenging for antibody-based FcRn modulators compared to small molecules, as the target lacks major tissue isoforms and the extracellular domain is immunologically distinct. However, off-target effects may include modulation of albumin recycling and systemic IgG reduction, requiring careful monitoring of immune homeostasis.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (6)

Relevant trials from ClinicalTrials.gov

Active

2

Completed

2

Total Enrollment

231

By Phase

PHASE1: 1 · PHASE2: 2 · PHASE3: 1 · PHASE4: 1 · Unknown: 1

Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC E Recruiting

PHASE4 NCT07072988 n=50

Myasthenia Gravis, Generalized

Interventions: Efgartigimod

Sponsor: Centre Hospitalier Universitaire de Nice | Started: 2025-09-19

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip Recruiting

Unknown NCT07294170 n=70

Myasthenia Gravis, MG, gMG

Interventions: Efgartigimod IV, Empasiprubart IV

Sponsor: argenx | Started: 2025-12-19

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome Completed

PHASE2 NCT06203457 n=24

Primary Sjögren's Syndrome

Interventions: Efgartigimod

Sponsor: argenx | Started: 2023-11-29

A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigi Completed

PHASE1 NCT04564066 n=54

Healthy Volunteers

Interventions: efgartigimod IV, efgartigimod PH20 SC

Sponsor: argenx | Started: 2020-08-18

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS Terminated

PHASE2 NCT05918978 n=33

Post-COVID Postural Orthostatic Tachycar

Interventions: Efgartigimod

Sponsor: argenx | Started: 2023-06-20

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) Withdrawn

PHASE3 NCT04274452

Primary Immune Thrombocytopenia (ITP)

Interventions: efgartigimod, Placebo

Sponsor: argenx | Started: 2020-06-29

Linked Hypotheses (1)

Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation0.773

Linked Experiments (1)

Pharmacokinetic evaluation of humanized mAbs in IgG1-Fc humanized mice0.800

Scoring Dimensions

Knowledge Graph (20)

associated with (3)

FCGRT→neurodegenerationFCGRT→Myasthenia GravisFCGRT→SARS-CoV-2

co discussed (11)

LRP1→FCGRTLDLR→FCGRTTFR1→FCGRTAQP4→FCGRTCAV1→FCGRT

▸ Show 6 more

ABCB1→FCGRTOCLN→FCGRTAPOE→FCGRTMTNR1A→FCGRTMTNR1B→FCGRTFCGRT→CLDN5

expressed in (1)

implicated in (1)

FCGRT→neurodegeneration

modulates (1)

FCGRT→Anti-SARS-CoV-2 Antibodies

participates in (1)

FCGRT→Neonatal Fc receptor / antibody transcytosis

regulates (1)

FCGRT→IVIg Effectiveness

targets (1)

h-23a3cc07→FCGRT

Debate History (1)

Should FCGRT (Fc fragment of IgG receptor and transporter) be prioritized as a t2026-04-21